C-kit as a target in the treatment of acute myelogenous leukemia

Curr Hematol Rep. 2005 Jan;4(1):51-8.

Abstract

Acute myelogenous leukemia (AML) is a difficult disease to treat. Novel treatment strategies, including molecular targeted therapy, are currently being explored. The c-kit receptor represents a potential therapeutic target for AML. The receptor is expressed on more than 10% of blasts in 64% of de novo AMLs and 95% of relapsed AMLs. C-kit mediates proliferation and anti-apoptotic effects in AML. This review will discuss the biology of c-kit in normal and malignant hematopoiesis, and the recent clinical trials targeting c-kit in AML.

Publication types

  • Review

MeSH terms

  • Acute Disease
  • Angiogenesis Inhibitors / pharmacology
  • Angiogenesis Inhibitors / therapeutic use
  • Animals
  • Antineoplastic Agents / pharmacology*
  • Antineoplastic Agents / therapeutic use
  • Benzamides
  • Cell Line, Tumor
  • Clinical Trials as Topic
  • Hematopoiesis
  • Humans
  • Imatinib Mesylate
  • Indoles / pharmacology
  • Indoles / therapeutic use
  • Leukemia, Myeloid / drug therapy*
  • Leukemia, Myeloid / genetics
  • Mice
  • Piperazines / therapeutic use
  • Protein Kinase Inhibitors / pharmacology*
  • Protein Kinase Inhibitors / therapeutic use
  • Protein Processing, Post-Translational / drug effects
  • Proto-Oncogene Proteins c-kit / chemistry
  • Proto-Oncogene Proteins c-kit / drug effects*
  • Proto-Oncogene Proteins c-kit / genetics
  • Proto-Oncogene Proteins c-kit / physiology
  • Pyrimidines / therapeutic use
  • Pyrroles / pharmacology
  • Pyrroles / therapeutic use
  • Stem Cell Factor / physiology*
  • Stem Cell Factor / therapeutic use

Substances

  • Angiogenesis Inhibitors
  • Antineoplastic Agents
  • Benzamides
  • Indoles
  • Piperazines
  • Protein Kinase Inhibitors
  • Pyrimidines
  • Pyrroles
  • Stem Cell Factor
  • Semaxinib
  • Imatinib Mesylate
  • orantinib
  • Proto-Oncogene Proteins c-kit